Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.
Inspection Record
Gland Pharma Limited — FDA 483 Findings
Inspectors Ashar P ParikhThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room to produce aseptic conditions.
Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
Similar findings at other companies
GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.
- Fresenius Kabi USA, LLC2026-05-14 · US FDASimilar to finding 3 Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity…
- Greer Laboratories, Inc.2024-12-18 · US FDASimilar to finding 3 Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity…
- Shilpa Medicare Limited2026-05-29 · US FDASimilar to finding 3 Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity…
- Pharmathen International S.A.2025-11-21 · US FDASimilar to finding 3 Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity…
- Instituto Grifols, S.A.2023-11-17 · US FDASimilar to finding 3 Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity…
A record as of the US FDA document published on 2026-10-20. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.